Links between donor macrosteatosis, interleukin-33 and complement after liver transplantation

doi:10.5500/wjt.v10.i5.117

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 5

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11159)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-6) series.

Item

Count

PDF

422

WORD

289

HTML

4125

Figures (1-2)

615

Tables (1-6)

579

Sum=6030

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

516

Download

1583

Sum=2099

Publishing Process of This Article

Item

Count

Browse

1172

Download

1871

Sum=3043

May 29, 2020 (publication date) through Feb 16, 2026

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Retrospective Cohort Study

World J Transplant. May 29, 2020; 10(5): 117-128
Published online May 29, 2020. doi: 10.5500/wjt.v10.i5.117

Links between donor macrosteatosis, interleukin-33 and complement after liver transplantation

Kelley Núñez, Mohammad Hamed, Daniel Fort, David Bruce, Paul Thevenot, Ari Cohen

Kelley Núñez, Mohammad Hamed, Paul Thevenot, Institute of Translational Research, Ochsner Clinic Foundation, New Orleans, LA 70121, United States

Daniel Fort, Center for Outcomes and Health Services Research, Research Administration, Ochsner Clinic Foundation, New Orleans, LA 70121, United States

David Bruce, Ari Cohen, Multi-Organ Transplant Program, Ochsner Clinic Foundation, New Orleans, LA 70121, United States

Author contributions: Thevenot P and Cohen A designed the research; Núñez K and Hamed M performed the research; Núñez K, Fort D, Bruce D, and Thevenot P analyzed the data; Núñez K wrote the manuscript; Hamed M, Thevenot P, and Cohen A revised the manuscript.

Institutional review board statement: This study was reviewed and approved by the Ochsner Institutional Review Board.

Informed consent statement: All patients in this study provided informed consent.

Conflict-of-interest statement: Authors have no conflict of interests to disclose.

Data sharing statement: No additional data are available for this study.

STROBE statement: Authors have read the STROBE Statement checklist of items and the manuscript was prepared and revised according to the STROBE Statement checklist of items.

Corresponding author: Ari Cohen, MD, Professor, Surgeon, Multi-Organ Transplant, Ochsner Clinic Foundation, 1514 Jefferson Hwy, New Orleans, LA 70121, United States. acohen@ochsner.org

Received: December 31, 2019
Peer-review started: December 31, 2019
First decision: March 26, 2020
Revised: April 7, 2020
Accepted: May 5, 2020
Article in press: May 5, 2020
Published online: May 29, 2020
Processing time: 149 Days and 11 Hours

ARTICLE HIGHLIGHTS

Research background

Due to the rise in nonalcoholic fatty liver disease, grafts with macrosteatosis will become more frequent in the donor pool. The use of macrosteatotic donor grafts for transplantation are associated with increased risk of graft failure and patient mortality. Factors that predict which macrosteatotic grafts are safe for transplantation remain limited.

Research motivation

The motivation for this study was to identify biomarkers immediately following reperfusion during transplantation with macrosteatotic grafts that predict increased injury post-transplant.

Research objectives

The objective of this study was to investigate the relationship between interleukin-33 and activated complement (C3a and C5a) with liver dysfunction in recipients immediately following liver reperfusion transplanted with either < 30% or ≥ 30% macrosteatotic grafts.

Research methods

The cohort consisted of recipients transplanted with either < 30% or ≥ 30% macrosteatotic grafts. Blood was collected immediately following reperfusion with quantification of interleukin-33 and activated complement (C3a and C5a) levels. Punch biopsies in a subset of donor grafts (n = 22) were used for microRNA expression analysis.

Research results

Recipients transplanted with ≥ 30% macrosteatotic grafts had significantly higher ALT and AST levels, increased risk of early allograft dysfunction, and higher levels of interleukin-33 and activated complement (C3a and C5a) post-transplant compared to recipients transplanted with < 30% macrosteatotic grafts. Additionally, upregulation of pro-inflammatory genes were found in macrosteatotic grafts.

Research conclusions

Quantification of interleukin-33 and activated complement (C3a and C5a) immediately following reperfusion during transplantation can provide insight into which recipients are at increased risk of early allograft dysfunction.

Research perspectives

This study provides additional justification for targeting activated complement in macrosteatotic grafts prior to transplantation.